A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Exclusion Criteria

• •limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
• •inability to follow study requirements and schedule
• •treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other cancer therapy
• •serious medical illness at same time of study and/or significantly abnormal lab reports
• •lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
• •Women of childbearing potential not protected by highly effective contraceptive method of birth control OTHER than hormonal contraception (Part 4 only).
• •prior significant hearing or kidney problems
• •continued toxic effects of prior chemotherapy
• •cancers that cannot be physically measured (Part 2 only)
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.